Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.

Mullins CD, Montgomery R, Abernethy AP, Hussain A, Pearson SD, Tunis S; American Society of Clinical Oncology.

J Clin Oncol. 2012 Feb 20;30(6):661-6. doi: 10.1200/JCO.2011.35.5198. Epub 2012 Jan 17.

PMID:
22253467
2.

Lessons learned from independent central review.

Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

PMID:
19101138
3.

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

Stone AM, Bushnell W, Denne J, Sargent DJ, Amit O, Chen C, Bailey-Iacona R, Helterbrand J, Williams G; PhRMA working group.

Eur J Cancer. 2011 Aug;47(12):1763-71. doi: 10.1016/j.ejca.2011.02.011. Epub 2011 Mar 22.

PMID:
21435858
4.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

PMID:
22147736
5.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
6.

Uncertainty in assessing value of oncology treatments.

Mullins CD, Montgomery R, Tunis S.

Oncologist. 2010;15 Suppl 1:58-64. doi: 10.1634/theoncologist.2010-S1-58.

7.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

8.

Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

[No authors listed]

Drugs R D. 2005;6(3):178-85. Review.

PMID:
15869322
9.

Reimbursement for cancer treatment: coverage of off-label drug indications.

American Society of Clinical Oncology.

J Clin Oncol. 2006 Jul 1;24(19):3206-8. Epub 2006 May 22.

PMID:
16717290
10.

Accelerated approval of oncology products: the food and drug administration experience.

Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R.

J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21. Review.

PMID:
21422403
11.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
12.

Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.

Cheng JS, Lee MJ, Massicotte E, Ashman B, Gruenberg M, Pilcher LE, Skelly AC.

Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4. Review.

PMID:
21952186
13.
14.

NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.

Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Marc Stewart F, Tyler T, Vose JM, Weinstein S, Li EC, Demartino J; NCCN Oncology Risk Evaluation and Mitigation Strategies (REMS) Work Group.

J Natl Compr Canc Netw. 2010 Sep;8 Suppl 7:S7-S27.

PMID:
20947724
15.

Tackling off-label use of anticancer drugs.

Perrone F, de Braud F, Labianca R, Tomino C, Roila F.

J Clin Oncol. 2012 Aug 1;30(22):2800; author reply 2801. doi: 10.1200/JCO.2012.42.9480. Epub 2012 Jul 2. No abstract available.

PMID:
22753903
16.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
17.

Systematic review: reliability of compendia methods for off-label oncology indications.

Abernethy AP, Raman G, Balk EM, Hammond JM, Orlando LA, Wheeler JL, Lau J, McCrory DC.

Ann Intern Med. 2009 Mar 3;150(5):336-43. Epub 2009 Feb 16. Review. Erratum in: Ann Intern Med. 2009 Apr 21;150(8):571.

PMID:
19221366
18.

Methodological recommendations for comparative research on the treatment of chronic wounds.

Sonnad SS, Goldsack JC, Mohr P, Tunis S.

J Wound Care. 2013 Sep;22(9):470-80.

PMID:
24005781
19.

Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers.

Sonnad SS, Mullins CD, Whicher D, Goldsack JC, Mohr PE, Tunis SR.

Contemp Clin Trials. 2013 Nov;36(2):356-61. doi: 10.1016/j.cct.2013.08.008. Epub 2013 Aug 31.

PMID:
23999501
20.

Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.

Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP.

Int J Risk Saf Med. 2012 Jan 1;24(3):137-46. doi: 10.3233/JRS-2012-0567.

PMID:
22936056

Supplemental Content

Support Center